Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
Thomas Jefferson University · with University of Rochester · NCT06419803
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 430
- US sites recruiting
- 1
- Study start
- September 1, 2024
- Record last updated
- November 22, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a Strict and permissive threshold. The Strict study arm target range will be 65-120 mg/dL, with time in range goal of 70%. The permissive study arm target range will be 65-140 mg/dL, with target time in range goal of 70%.
Being studied: Insulin
Conditions: Gestational Diabetes; Pregnancy Related
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Live, non-anomalous fetus
- Literacy in English, Spanish, Mandarin, or Arabic
- Patients are also required to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.
Exclusion Criteria
- \<18 years at EDD
- pre-existing diabetes or diagnosis of GDM prior to 24 weeks
- multi-fetal gestation
- known major fetal anomaly
- known allergy to insulin
- chronic maternal corticosteroid use
- diagnosis of GDM based on finger sticks alone
- patients who have contraindication to oral glucose tolerance test
- a primary language other than English, Spanish, Mandarin, or Arabic
Recruiting US locations
Thomas Jefferson University
Philadelphia, PA 19107
Site contact: Kavisha Khanuja, MD
Study contacts (from the official record)
- Kavisha Khanuja, MD · 2159555000 · kxk334@jefferson.edu
- Rodney McLaren Jr, MD · 2159555000 · rodney.mclaren@jefferson.edu
Similar studies in Pennsylvania
All diabetes studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- Erie, PA + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
Pharmacogenetics of Response to GLP1R Agonists
University of Maryland, Baltimore
- Location
- Lancaster, PA
- Eligibility basics
- Ages 18–89
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Philadelphia, PA + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Smithfield, PA + 11 other US sites
- Eligibility basics
- Ages 10–17